文献速递免疫规划慢病防控与筛查

养老院居民接种两剂Comirnaty疫苗后按既往感染状态划分的抗SARS-CoV-2体液免疫应答

Humoral anti-SARS-CoV-2 immune response after two doses of Comirnaty vaccine in nursing home residents by previous infection status.
PubMed 文献 · Vaccine · 2021-12-03

在69名养老院居民中,接种两剂Comirnaty疫苗后2个月全部(100%)抗SARS-CoV-2抗体阳性;接种前已有感染者抗刺突1 IgG和中和抗体滴度显著高于无既往感染者;疫苗血清对B.1.351和P.1变异株RBD结合能力较野生型显著降低,对B.1.1.7 RBD未降低。

要点

  • 69名养老院居民接种两剂Comirnaty后2个月抗体阳性率100%。
  • 接种前感染组抗刺突1 IgG中位数55726 vs 无感染组1314任意单位,p<0.001。
  • 疫苗血清对B.1.351和P.1变异株RBD结合能力较野生型显著降低,对B.1.1.7未降低。

核心结论

  • 所有养老院居民接种Comirnaty疫苗后均产生体液应答,但其强度似乎取决于接种前血清学状态。
  • 作者提出老年人应接种多少剂疫苗及保护能持续多久的问题。

研究设计与样本

  • 研究纳入69名居住在养老院的患者,均接种了推荐的两剂Comirnaty(辉瑞-BioNTech®)疫苗。
  • 按接种前SARS-CoV-2血清阳性状态分为有既往感染组和无既往感染组,比较体液免疫应答。

主要发现

  • 全部69名患者(100%)在接种后2个月检测抗SARS-CoV-2抗体阳性。
  • 接种前有感染组抗刺突1 IgG中位数55726(四分位距14463-78852)任意单位 vs 无既往感染组1314(272-1249)任意单位,p<0.001。
  • 接种前有感染组中和抗体滴度中位数704(320-1280) vs 无既往感染组47(20-40),p<0.001。
  • 从接种前到接种后,IgG和中和抗体分别观察到49倍和8倍升高。
  • 与野生型受体结合域(RBD)相比,疫苗血清对B.1.351和P.1变异株RBD的结合能力显著降低,对B.1.1.7 RBD未降低。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Coronavirus disease 2019 (COVID-19) is associated with increased morbidity and mortality in older adults. Although the advent of the first vaccines has significantly reduced these rates, data on older adults in clinical trials are scarce. OBJECTIVES: We quantified and compared the humoral response in individuals with vs. without pre-existing seropositivity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in a cohort of 69 patients living in a nursing home and who had received the recommended two doses of the Comirnaty (Pfizer-BioNTech®) vaccine. RESULTS: All 69 patients (100%) tested positive for antibodies against SARS-CoV-2 at 2 months post-vaccination. Residents with a pre-vaccination infection had significantly higher titers of anti-spike 1 IgG than those with no prior infection (median [interquartile range]: 55,726 [14463-78852] vs. 1314 [272-1249] arbitrary units, respectively; p < 0.001). The same result was observed for neutralizing antibodies titers (704 [320-1280] vs. 47 [20-40] respectively; p < 0.001). Between the pre-vaccination and post-vaccination periods, for IgG and neutralizing antibodies, we observed a 49 and 8-fold increase respectively. In comparison to the wild-type Receptor Binding Domain (RBD), the binding capacity of these vaccine sera was significantly decreased on the B.1.351 and P.1 variants RBD but not decreased with respect to the B.1.1.7 RBD. Although all nursing home residents developed a humoral response following Comirnaty vaccine, its intensity appeared to depend on the pre-vaccination serological status. CONCLUSION: Our results raise the question of how many doses of vaccine should be administered in older and how long the protection will be effective.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Helle F, Moyet J, Demey B, et al. Humoral anti-SARS-CoV-2 immune response after two doses of Comirnaty vaccine in nursing home residents by previous infection status. Vaccine. 2021. PMID: 34893341. doi:10.1016/j.vaccine.2021.11.086

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。